Skip to main content
SpringerLink
Log in

Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurobehavioral disorder related to clinically significant levels of inattention, hyperactivity, and/or impulsivity. ADHD begins in childhood and symptoms persist into adulthood for the majority of those with the disorder. Associated features of ADHD include emotion dysregulation and cognitive impairments, which contribute to the considerable functional impairments in this disorder. Current approved treatments are reasonably effective; however, a significant need remains for new pharmacotherapies, both for individuals who do not achieve a full therapeutic response and for symptoms that are under-treated including cognition and emotion regulation. The striking relationship between ADHD and cigarette smoking and the known effects of nicotine on cognition has spurred research into the therapeutic potential of nicotinic agents for ADHD. Although there are no approved medications for ADHD that target nicotinic acetylcholine receptor (nAChR) function, results from many trials of nicotinic drugs are available and reviewed in this article. ADHD symptoms were reduced in the majority of published studies of nicotine and novel α4β2 nicotinic agonists in adult ADHD. The drugs were generally well tolerated, with mild to moderate side effects reported, which were largely consistent with cholinergic stimulation and included nausea, dizziness, and gastrointestinal distress. Within-subject crossover study designs were used in the majority of positive studies. This design may be particularly useful in ADHD trials because it minimizes variability in this notoriously heterogeneous diagnostic group. In addition, many studies found evidence for a beneficial effect of nicotinic stimulation on cognitive and emotional domains. Thus, targeting nAChRs in ADHD appears to have a modest clinical benefit in adult ADHD. Continued refinement of nAChR agonists with greater specificity and fewer side effects may lead to even more effective nAChR agonists for ADHD. Future clinical trials in ADHD should include direct measures of neuropsychological performance and emotion regulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8.

    Article  PubMed  Google Scholar 

  2. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.

    Article  PubMed  Google Scholar 

  3. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–27.

    Article  PubMed  Google Scholar 

  4. Lange KW, et al. The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2010;2(4):241–55.

    Article  PubMed Central  PubMed  Google Scholar 

  5. American Psychiatic Association. Diagnostic and statisical manual of mental disorders (2nd ed.). 2nd ed. Washington, DC: American Psychiatric Association; 1968.

    Google Scholar 

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd ed.). 3rd ed. Washington, DC: American Psychiatric Association; 1980.

    Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington, DC: American Psychiatric Association; 2000.

    Google Scholar 

  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). 4th ed. Washington, DC: US Government Printing Office; 1994.

    Google Scholar 

  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington: American Psychiatric Association; 2013.

    Google Scholar 

  10. Castellanos FX. DSM-5 ADHD and Disruptive Behavior Disorders Work Group. 2009 [cited 2014 April]. Available from: http://www.DSM-5.org/progressreports/pages/0904dsm-vadhdanddisruptivebehaviordisordersworkgroup.aspx.

  11. Willcutt EG, et al. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 2012;121(4):991–1010.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Lahey BB, Willcutt EG. Predictive validity of a continuous alternative to nominal subtypes of attention-deficit/hyperactivity disorder for DSM-V. J Clin Child Adolesc Psychol. 2010;39(6):761–75.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Thompson RA. Emotion regulation: a theme in search of definition. Monogr Soc Res Child Dev. 1994;59(2–3):25–52.

    Article  CAS  PubMed  Google Scholar 

  14. Shaw P, et al. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276–93.

    Article  PubMed  Google Scholar 

  15. Stringaris A. Irritability in children and adolescents: a challenge for DSM-5. Eur Child Adolesc Psychiatry. 2011;20(2):61–6.

    Article  PubMed  Google Scholar 

  16. Sobanski E, et al. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence. J Child Psychol Psychiatry. 2010;51(8):915–23.

    Article  PubMed  Google Scholar 

  17. Stringaris A, Goodman R. Mood lability and psychopathology in youth. Psychol Med. 2009;39(8):1237–45.

    Article  CAS  PubMed  Google Scholar 

  18. Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health. 2010;46(3):209–17.

    Article  PubMed  Google Scholar 

  19. Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry. 2010;49(5):503–13.

    PubMed  Google Scholar 

  20. Amiri S, et al. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):145–9.

    Article  CAS  PubMed  Google Scholar 

  21. Biederman J, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–63.

    Article  CAS  PubMed  Google Scholar 

  22. Spencer TJ, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–79.

    Article  CAS  PubMed  Google Scholar 

  23. Wigal SB, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275–89.

    Article  PubMed  Google Scholar 

  24. Barkley RA. Attention-deficit/hyperactivity disorder, self-regulation, and time: toward a more comprehensive theory. J Dev Behav Pediatr. 1997;18(4):271–9.

    Article  CAS  PubMed  Google Scholar 

  25. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121(1):65–94.

    Article  CAS  PubMed  Google Scholar 

  26. Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry Allied Discip. 1996;37(1):51–87.

    Article  CAS  Google Scholar 

  27. Nikolas MA, Nigg JT. Neuropsychological performance and attention-deficit hyperactivity disorder subtypes and symptom dimensions. Neuropsychology. 2013;27(1):107–20.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Nigg JT, et al. Executive functions and ADHD in adults: evidence for selective effects on ADHD symptom domains. J Abnorm Psychol. 2005;114(4):706–17.

    Article  PubMed  Google Scholar 

  29. Martel M, Nikolas M, Nigg JT. Executive function in adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1437–44.

    Article  PubMed  Google Scholar 

  30. Fischer M, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol. 1990;58(5):580–8.

    Article  CAS  PubMed  Google Scholar 

  31. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev. 2006;26(4):466–85.

    Article  PubMed  Google Scholar 

  32. Seidman LJ, et al. Toward defining a neuropsychology of attention deficit-hyperactivity disorder: performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol. 1997;65(1):150–60.

    Article  CAS  PubMed  Google Scholar 

  33. Gualtieri CT, Johnson LG. Medications do not necessarily normalize cognition in ADHD patients. J Atten Disord. 2008;11(4):459–69.

    Article  PubMed  Google Scholar 

  34. Wilens TE, et al. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol. 1995;15(4):270–9.

    Article  CAS  PubMed  Google Scholar 

  35. Spencer T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–63.

    Article  CAS  PubMed  Google Scholar 

  36. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007;74(8):1212–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Behav Brain Res. 2006;175(2):201–11.

    Article  CAS  PubMed  Google Scholar 

  38. Levin ED, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123(1):55–63.

    Article  CAS  Google Scholar 

  39. Singh A, Potter A, Newhouse P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs. 2004;7(12):1096–103.

    CAS  PubMed  Google Scholar 

  40. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189–202.

    Article  PubMed  Google Scholar 

  41. Conners CK, et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67–73.

    CAS  PubMed  Google Scholar 

  42. Gehricke JG, et al. Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder. Psychol Addict Behav. 2009;23(4):644–55.

    Article  PubMed  Google Scholar 

  43. Poltavski DV, Petros T. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol Behav. 2006;87(3):614–24.

    Article  CAS  PubMed  Google Scholar 

  44. Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav. 2008;88(4):407–17.

    Article  CAS  PubMed  Google Scholar 

  45. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2004;176(2):182–94.

    Article  CAS  Google Scholar 

  46. Shytle RD, et al. A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder. World J Biol Psychiatry. 2002;3(3):150–5.

    Article  PubMed  Google Scholar 

  47. Wilens TE, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156(12):1931–7.

    CAS  PubMed  Google Scholar 

  48. Wilens TE, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59(11):1065–70.

    Article  CAS  PubMed  Google Scholar 

  49. Potter AS, Bucci DJ, Newhouse PA. Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. Psychopharmacology (Berl). 2012;220(2):331–40.

    Article  CAS  Google Scholar 

  50. Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Hum Psychopharmacol. 2009;24(4):309–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Levin ED, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2001;9(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  52. Conners CK, et al. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257–68.

    Article  CAS  PubMed  Google Scholar 

  53. Gehricke JG, et al. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: a preliminary examination. Nicotine Tob Res. 2006;8(1):37–47.

    Article  CAS  PubMed  Google Scholar 

  54. Giniatullin R, Nistri A, Yakel JL. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci. 2005;28(7):371–8.

    Article  CAS  PubMed  Google Scholar 

  55. Newhouse P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91–101.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Biederman J, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006;26(2):163–6.

    Article  CAS  PubMed  Google Scholar 

  57. Wilens TE, et al. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000;10(3):217–22.

    Article  CAS  PubMed  Google Scholar 

  58. Wilens TE, et al. An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(6):947–55.

    Article  PubMed  Google Scholar 

  59. Apostol G, et al. Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012;219(3):715–25.

    Article  CAS  Google Scholar 

  60. Bain EE, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73(6):783–9.

    Article  CAS  PubMed  Google Scholar 

  61. Wilens TE, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011;50(1):3–84 e1.

  62. Bain EE, et al. A randomized, double-blind, placebo-controlled phase 2 study of alpha4beta2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology. 2013;38(3):405–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Jucaite A, et al. A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2014;231(6):1251–65.

    Article  CAS  Google Scholar 

  64. Potter AS, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry. 2014;75(3):207–14.

    Article  CAS  PubMed  Google Scholar 

  65. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–63.

    Article  PubMed  Google Scholar 

  66. Joober R. On the simple and the complex in psychiatry, with reference to DSM 5 and research domain criteria. J Psychiatry Neurosci. 2013;38(3):148–51.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Tanaka Y, et al. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. J Child Adolesc Psychopharmacol. 2013;23(4):262–70.

    Article  CAS  PubMed  Google Scholar 

  68. Solanto M, et al. Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):663–71.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Mattingly G, et al. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. Innov Clin Neurosci. 2012;9(5–6):22–30.

    PubMed Central  PubMed  Google Scholar 

  70. Gorman EB, et al. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):808–16.

    Article  PubMed  Google Scholar 

  71. Picciotto MR. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci. 2003;24(9):493–9.

    Article  CAS  PubMed  Google Scholar 

  72. Perkins KA. Baseline-dependency of nicotine effects: a review. Behav Pharmacol. 1999;10(6–7):597–615.

    Article  CAS  PubMed  Google Scholar 

  73. Rapoport JL, et al. Dextroamphetamine: its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry. 1980;37(8):933–43.

    Article  CAS  PubMed  Google Scholar 

  74. Rapoport JL, Inoff-Germain G. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord. 2002;6(Suppl 1):S57–60.

    PubMed  Google Scholar 

  75. Adler LA, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011;123(5):71–9.

    Article  PubMed  Google Scholar 

  76. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184–91.

    Article  PubMed  Google Scholar 

  77. Bickel WK, Odum AL, Madden GJ. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology. 1999;146(4):447–54.

    Article  CAS  PubMed  Google Scholar 

  78. Doran N, et al. Impulsivity and smoking relapse. Nicotine Tob Res. 2004;6(4):641–7.

    Article  PubMed  Google Scholar 

  79. Krishnan-Sarin S, et al. Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend. 2007;88(1):79–82.

    Article  PubMed Central  PubMed  Google Scholar 

  80. Mitchell SH. Measuring impulsivity and modeling its association with cigarette smoking. Behav Cogn Neurosci Rev. 2004;3(4):261–75.

    Article  PubMed  Google Scholar 

  81. Ryan KK, Mackillop J, Carpenter MJ. The relationship between impulsivity, risk-taking propensity and nicotine dependence among older adolescent smokers. Addict Behav. 2013;38(1):1431–4.

    Article  PubMed Central  PubMed  Google Scholar 

  82. Heffner JL, et al. Relationship between cigarette smoking and childhood symptoms of inattention and hyperactivity/impulsivity in alcohol-dependent adults without attention-deficit hyperactivity disorder. Nicotine Tob Res. 2010;12(3):243–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142–7.

    Article  PubMed  Google Scholar 

  84. Avila MT, et al. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology. 2003;28(12):2184–91.

    CAS  PubMed  Google Scholar 

  85. Barr RS, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008;33(3):480–90.

    Article  CAS  PubMed  Google Scholar 

  86. Barr RS, et al. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry. 2008;63(11):1061–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Jubelt LE, et al. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl). 2008;199(1):89–98.

    Article  CAS  Google Scholar 

  88. Martin-Solch C, et al. Changes in brain activation associated with reward processing in smokers and nonsmokers: a positron emission tomography study. Exp Brain Res. 2001;139(3):278–86.

    Article  CAS  PubMed  Google Scholar 

  89. Wignall ND, de Wit H. Effects of nicotine on attention and inhibitory control in healthy nonsmokers. Exp Clin Psychopharmacol. 2011;19(3):183–91.

    Article  CAS  PubMed  Google Scholar 

  90. Ryan KK, Dube SL, Potter AS. Rate dependent effects of acute nicotine on risk taking in young adults are not related to ADHD diagnosis. Pharmacol Biochem Behav. 2013;103(3):652–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Grant No. K23MH079216 to Dr. Potter. No funding was specifically received for the preparation of this article. Dr. Potter, Mr. Schaubhut, and Ms. Shipman have no financial conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Clinical Neuroscience Research Unit, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT, 05401, USA

    Alexandra S. Potter, Geoffrey Schaubhut & Megan Shipman

Authors
  1. Alexandra S. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey Schaubhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan Shipman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra S. Potter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Potter, A.S., Schaubhut, G. & Shipman, M. Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date. CNS Drugs 28, 1103–1113 (2014). https://doi.org/10.1007/s40263-014-0208-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0208-9

Keywords

Search

Navigation